Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect

Oncotarget

Volumn 7, Issue 47, 2016, Pages 76613-76627

  Kleibeuker, Esther A ^a   Fokas, Emmanouil ^b   Allen, Philip D ^b   Kersemans, Veerle ^b   Griffioen, Arjan W ^a   Beech, John ^b   Im, Jaehong H ^b   Smart, Sean C ^b   Castricum, Kitty C ^a   van den Berg, Jaap ^a   Schulkens, Iris A ^a   Hill, Sally A ^b   Harris, Adrian L ^c   Slotman, Ben J ^a   Verheul, Henk M ^a   Muschel, Ruth J ^b   Thijssen, Victor L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Angiogenesis; Cancer; Combination therapy; Radiotherapy; Tumor perfusion

Indexed keywords

PLACENTAL GROWTH FACTOR; SUNITINIB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; COLON CARCINOMA; COLORECTAL CARCINOMA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; ECHOGRAPHY; HT 29 CELL LINE; HUMAN; HUMAN CELL; HYPOXIA; LOW DRUG DOSE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; RADIATION DOSE; RADIOTHERAPY INDUCED TUMOR PERFUSION; TREATMENT DURATION; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; CHEMORADIOTHERAPY; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROCEDURES; RADIATION RESPONSE; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA; MAGNETIC RESONANCE IMAGING; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RADIOTHERAPY; ULTRASONOGRAPHY;

EID: 84998879940     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12814     Document Type: Article

References (65)

1. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953; 26: 638-48. doi: 10.1259/0007-1285-26-312-638.
2. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955; 9: 539-49.
3. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and plateletderived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res. 2002; 62: 1702-6.
4. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003; 300: 1155-9. doi: 10.1126/science.1082504.
5. Kleibeuker EA, Griffioen AW, Verheul HM, Slotman BJ, Thijssen VL. Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist Updat. 2012; 15: 173-82. doi: 10.1016/j.drup.2012.04.002.
6. Corn PG, Song DY, Heath E, Maier J, Meyn R, Kuban D, DePetrillo TA, Mathew P. Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study. Int J Radiat Oncol Biol Phys. 2013; 86: 540-5. doi: 10.1016/j.ijrobp.2012.12.029.
7. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370: 709-22. doi: 10.1056/NEJMoa1308345.
8. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res. 2004; 64: 3731-6.
9. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell. 2004; 6: 553-63.
10. Jain RK., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science. 2005; 307: 58-62.
11. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011; 10: 417-27. doi: 10.1038/nrd3455.
12. Weiss A, Bonvin D, Berndsen RH, Scherrer E, Wong TJ, Dyson PJ, Griffioen AW, Nowak-Sliwinska P. Angiostatic treatment prior to chemo-or photodynamic therapy improves anti-tumor efficacy. Sci Rep. 2015; 5: 8990. doi: 10.1038/srep08990.
13. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell. 2007; 11: 83-95.
14. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med. 2004; 10: 145-7.
15. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003; 63: 4009-16.
16. Chi KH, Liao CS, Chang CC, Ko HL, Tsang YW, Yang KC, Mehta MP. Angiogenic blockade and radiotherapy in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2010; 78: 188-93. doi: 10.1016/j.ijrobp.2009.07.1725.
17. Kleibeuker EA, Ten Hooven MA, Castricum KC, Honeywell R, Griffioen AW, Verheul HM, Slotman BJ, Thijssen VL. Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction. Cancer Med. 2015; 4: 1003-15. doi: 10.1002/cam4.441.
18. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999; 59: 3374-8.
19. Ning S, Laird D, Cherrington JM, Knox SJ. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res. 2002; 157: 45-51.
20. Ning S, Tian J, Marshall DJ, Knox SJ. Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res. 2010; 70: 7591-9. doi: 10.1158/0008-5472.CAN-10-1639.
21. Riesterer O, Oehler-Jänne C, Jochum W, Broggini-Tenzer A, Vuong V, Pruschy M. Ionizing radiation and inhibition of angiogenesis in a spontaneous mammary carcinoma and in a syngenic heterotopic allograft tumor model: a comparative study. Radiat Oncol. 2011; 6: 66. doi: 10.1186/1748-717X-6-66.
22. Ager EI, Kozin SV, Kirkpatrick ND, Seano G, Kodack DP, Askoxylakis V, Huang Y, Goel S, Snuderl M, Muzikansky A, Finkelstein DM, Dransfield DT, Devy L, et al. Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy. J Natl Cancer Inst. 2015; 107: doi: 10.1093/jnci/djv017.
23. Nozue, Mutsumi, Isaka, Naohide, Fukao, Katashi. Overexpression of vascular endothelial growth factor after preoperative radiation therapy for rectal cancer Oncol Rep. 2001; 8: 1247-9.
24. Bayer C, Kielow A, Schilling D, Maftei CA, Zips D, Yaromina A, Baumann M, Molls M, Multhoff G. Monitoring PAI-1 and VEGF levels in 6 human squamous cell carcinoma xenografts during fractionated irradiation. Int J Radiat Oncol Biol Phys. 2012; 84: e409-17. doi: 10.1016/j.ijrobp.2012.04.033.
25. Cooper RA, West CM, Logue JP, Davidson SE, Miller A, Roberts S, Statford IJ, Honess DJ, Hunter RD. Changes in oxygenation during radiotherapy in carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 1999; 45: 119-26.
26. Dunst J, Hänsgen G, Lautenschläger C, Füchsel G, Becker A. Oxygenation of cervical cancers during radiotherapy and radiotherapy + cis-retinoic acid/interferon. Int J Radiat Oncol Biol Phys. 1999; 43: 367-73.
27. Mayr NA, Yuh WT, Magnotta VA, Ehrhardt JC, Wheeler JA, Sorosky JI, Davis CS, Wen BC, Martin DD, Pelsang RE, Buller RE, Oberley LW, Mellenberg DE, et al. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int J Radiat Oncol Biol Phys. 1996; 36: 623-33.
28. Fenton BM, Paoni SF, Ding I. Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors. Cancer Res. 2004; 64: 5712-9. doi: 10.1158/0008-5472.CAN-04-0434.
29. Song C, Hong BJ, Bok S, Lee CJ, Kim YE, Jeon SR, Wu HG, Lee YS, Cheon GJ, Paeng JC, Carlson DJ, Kim HJ, Ahn GO. Real-time Tumor Oxygenation Changes After Single High-dose Radiation Therapy in Orthotopic and Subcutaneous Lung Cancer in Mice: Clinical Implication for Stereotactic Ablative Radiation Therapy Schedule Optimization. Int J Radiat Oncol Biol Phys. 2016; 95: 1022-31. doi: 10.1016/j.ijrobp.2016.01.064.
30. Potiron VA, Abderrahmani R, Clément-Colmou K, Marionneau-Lambot S, Oullier T, Paris F, Supiot S. Improved functionality of the vasculature during conventionally fractionated radiation therapy of prostate cancer. PLoS One. 2013; 8: e84076. doi: 10.1371/journal. pone.0084076.
31. De Keyzer F, Vandecaveye V, Thoeny H, Chen F, Ni Y, Marchal G, Hermans R, Nuyts S, Landuyt W, Bosmans H. Dynamic contrast-enhanced and diffusion-weighted MRI for early detection of tumoral changes in singledose and fractionated radiotherapy: evaluation in a rat rhabdomyosarcoma model. Eur Radiol. 2009; 19: 2663-71. doi: 10.1007/s00330-009-1451-1.
32. Zhang Q, Yang H, Kang SJ, Wang Y, Wang GD, Coulthard T, Grossniklaus HE. In vivo high-frequency, contrastenhanced ultrasonography of uveal melanoma in mice: imaging features and histopathologic correlations. Invest Ophthalmol Vis Sci. 2011; 52: 2662-8. doi: 10.1167/iovs.10-6794.
33. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization Clin Cancer Res. 2007; 13: 3395-402.
34. Kleibeuker EA, Ten Hooven MA, Verheul HM, Slotman BJ, Thijssen VL. Combining radiotherapy with sunitinib: lessons (to be) learned. Angiogenesis. 2015; doi: 10.1007/s10456-015-9476-3.
35. Janssen MH, Aerts HJ, Kierkels RG, Backes WH, Ollers MC, Buijsen J, Lambin P, Lammering G. Tumor perfusion increases during hypofractionated short-course radiotherapy in rectal cancer: sequential perfusion-CT findings. Radiother Oncol. 2010; 94: 156-60. doi: 10.1016/j. radonc.2009.12.013.
36. Shibuya K, Tsushima Y, Horisoko E, Noda SE, Taketomi-Takahashi A, Ohno T, Amanuma M, Endo K, Nakano T. Blood flow change quantification in cervical cancer before and during radiation therapy using perfusion CT. J Radiat Res. 2011; 52: 804-11.
37. Hohlweg-Majert B, Ristow O, Gust K, Kehl V, Wolff KD, Pigorsch S. Impact of radiotherapy on microsurgical reconstruction of the head and neck. J Cancer Res Clin Oncol. 2012; 138: 1799-811. doi: 10.1007/s00432-012-1263-6.
38. Chen FH, Fu SY, Yang YC, Wang CC, Chiang CS, Hong JH. Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway. Int J Radiat Oncol Biol Phys. 2013; 86: 777-84. doi: 10.1016/j.ijrobp.2013.02.036.
39. Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiationinduced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res. 2012; 177: 311-27.
40. Song C, Hong BJ, Bok S, Lee CJ, Kim YE, Jeon SR, Wu HG, Lee YS, Cheon GJ, Paeng JC, Carlson DJ, Kim HJ, Ahn GO. Real-time Tumor Oxygenation Changes After Single High-dose Radiation Therapy in Orthotopic and Subcutaneous Lung Cancer in Mice: Clinical Implication for Stereotactic Ablative Radiation Therapy Schedule Optimization. Int J Radiat Oncol Biol Phys. 2016; 95: 1022-31. doi: 10.1016/j.ijrobp.2016.01.064.
41. Dalrymple SL, Becker RE, Zhou H, DeWeese TL, Isaacs JT. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. Prostate. 2012; 72: 638-48. doi: 10.1002/pros.21467.
42. Crokart N, Jordan BF, Baudelet C, Ansiaux R, Sonveaux P, Grégoire V, Beghein N, DeWever J, Bouzin C, Feron O, Gallez B. Early reoxygenation in tumors after irradiation: determining factors and consequences for radiotherapy regimens using daily multiple fractions. Int J Radiat Oncol Biol Phys. 2005; 63: 901-10. doi: 10.1016/j. ijrobp.2005.02.038.
43. Speke AK, Hill RP. Repopulation kinetics during fractionated irradiation and the relationship to the potential doubling time, Tpot. Int J Radiat Oncol Biol Phys. 1995; 31: 847-56. doi: 10.1016/0360-3016(94)00496-X.
44. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005; 5: 516-25. doi: 10.1038/nrc1650.
45. Heissig B, Rafii S, Akiyama H, Ohki Y, Sato Y, Rafael T, Zhu Z, Hicklin DJ, Okumura K, Ogawa H, Werb Z, Hattori K. Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J Exp Med. 2005; 202: 739-50. doi: 10.1084/jem.20050959.
46. Lerman OZ, Greives MR, Singh SP, Thanik VD, Chang CC, Seiser N, Brown DJ, Knobel D, Schneider RJ, Formenti SC, Saadeh PB, Levine JP. Low-dose radiation augments vasculogenesis signaling through HIF-1-dependent and-independent SDF-1 induction. Blood. 2010; 116: 3669-76. doi: 10.1182/blood-2009-03-213629.
47. Wergin MC, Ballmer-Hofer K, Roos M, Achermann RE, Inteeworn N, Akens MK, Blattmann H, Kaser-Hotz B. Preliminary study of plasma vascular endothelial growth factor (VEGF) during low-and high-dose radiation therapy of dogs with spontaneous tumors. Vet Radiol Ultrasound. 2004; 45: 247-54.
48. Gotink KJ, Broxterman HJ, Honeywell RJ, Dekker H, de Haas RR, Miles KM, Adelaiye R, Griffioen AW, Peters GJ, Pili R, Verheul HM. Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience. 2014; 1: 844-53. doi: 10.18632/oncoscience.106.
49. Wachsberger PR, Burd R, Cardi C, Thakur M, Daskalakis C, Holash J, Yancopoulos GD, Dicker AP. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys. 2007; 67: 1526-37. doi: 10.1016/j.ijrobp.2006.11.011.
50. Peters NAJB, Richel DJ, Verhoeff JJC, Stalpers LJA. Bowel Perforation After Radiotherapy in a Patient Receiving Sorafenib Journal of Clinical Oncology. 2008; 26: 2405-6. doi: 10.1200/jco.2007.15.8451.
51. Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N, Farley C, Burris HA, Greco FA. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol. 2010; 28: 43-8. doi: 10.1200/JCO.2009.24.7353.
52. Jani A, Shaikh F, Barton S, Willis C, Banerjee D, Mitchell J, Hernandez SL, Hei T, Kadenhe-Chiweshe A, Yamashiro DJ, Connolly EP. High-Dose, Single-Fraction Irradiation Rapidly Reduces Tumor Vasculature and Perfusion in a Xenograft Model of Neuroblastoma. Int J Radiat Oncol Biol Phys. 2016; 94: 1173-80. doi: 10.1016/j.ijrobp.2015.12.367.
53. Hou H, Lariviere JP, Demidenko E, Gladstone D, Swartz H, Khan N. Repeated tumor pO(2) measurements by multi-site EPR oximetry as a prognostic marker for enhanced therapeutic efficacy of fractionated radiotherapy. Radiother Oncol. 2009; 91: 126-31. doi: 10.1016/j. radonc.2008.10.015.
54. Thanik VD, Chang CC, Lerman OZ, Greives MR, Le H, Warren SM, Schneider RJ, Formenti SC, Saadeh PB, Levine JP. Cutaneous low-dose radiation increases tissue vascularity through upregulation of angiogenic and vasculogenic pathways. J Vasc Res. 2010; 47: 472-80. doi: 10.1159/000313875.
55. Schulkens IA, Kleibeuker EA, Castricum KC, Griffioen AW, Thijssen VL. Examination of the role of galectins and galectin inhibitors in endothelial cell biology. Methods Mol Biol. 2015; 1207: 285-91. doi: 10.1007/978-1-4939-1396-1_18.
56. Dingemans AM, van den Boogaart V, Vosse BA, van Suylen RJ, Griffioen AW, Thijssen VL. Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer Mol Cancer. 2010; 9: 152. doi: 10.1186/1476-4598-9-152.
57. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001; 23: 291-9.
58. Kersemans V, Gilchrist S, Allen PD, Beech JS, Kinchesh www.impactjournals.com/oncotarget 76627 Oncotarget P, Vojnovic B, Smart SC. A resistive heating system for homeothermic maintenance in small animals. Magn Reson Imaging. 2015; 33: 847-51. doi: 10.1016/j.mri.2015.03.011.
59. Yarnykh VL., Actual flip-angle imaging in the pulsed steady state: a method for rapid three-dimensional mapping of the transmitted radiofrequency field. Magn Reson Med. 2007; 57: 192-200. doi: 10.1002/mrm.21120.
60. Christensen KA, Grant DM, Schulman EM, Walling C. Optimal determination of relaxation times of fourier transform nuclear magnetic resonance. Determination of spin-lattice relaxation times in chemically polarized species The Journal of Physical Chemistry. 1974; 78: 1971-7. doi: 10.1021/j100612a022.
61. Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, Gerig G. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006; 31: 1116-28. doi: 10.1016/j.neuroimage.2006.01.015.
62. Schabel MC, Parker DL. Uncertainty and bias in contrast concentration measurements using spoiled gradient echo pulse sequences. Phys Med Biol. 2008; 53: 2345-73. doi: 10.1088/0031-9155/53/9/010.
63. Singh A, Rathore RK, Haris M, Verma SK, Husain N, Gupta RK. Improved bolus arrival time and arterial input function estimation for tracer kinetic analysis in DCE-MRI. J Magn Reson Imaging. 2009; 29: 166-76. doi: 10.1002/jmri.21624.
64. Heilmann M, Walczak C, Vautier J, Dimicoli JL, Thomas CD, Lupu M, Mispelter J, Volk A. Simultaneous dynamic T1 and T2* measurement for AIF assessment combined with DCE MRI in a mouse tumor model. MAGMA. 2007; 20: 193-203. doi: 10.1007/s10334-007-0082-2.
65. Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res. 2012; 72: 239-48. doi: 10.1158/0008-5472. CAN-11-2263.